[1] [1] REBECCA V W, SOMASUNDARAM R, HERLYN M. Pre-clinical modeling of cutaneous melanoma ［J］. Nature Communications, 2020, 11(1): 2858.

[2] [2] SCHADENDORF D, VAN AKKOOI A C J, BERKING C, et al. Melanoma ［J］. Lancet, 2018, 392(10151): 971-984.

[3] [3] DESVIGNES T, PONTAROTTI P, FAUVEL C, et al. Nme protein family evolutionary history, a vertebrate perspective ［J］. BMC Evolutionary Biology, 2009, 9: 256.

[4] [4] PUTS G S, LEONARD M K, PAMIDIMUKKALA N V, et al. Nuclear functions of NME proteins ［J］. Laboratory Investigation, 2018, 98(2): 211-218.

[5] [5] BOISSAN M, DABERNAT S, PEUCHANT E, et al. The mammalian Nm23/NDPK family: from metastasis control to cilia movement ［J］. Molecular and Cellular Biochemistry, 2009, 329(1/2): 51-62.

[6] [6] MARINO N, NAKAYAMA J, COLLINS J W, et al. Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene ［J］. Cancer and Metastasis Reviews, 2012, 31(3/4): 593-603.

[7] [7] BANERJEE S, JHA H C, ROBERTSON E S. Regulation of the metastasis suppressor Nm23-H1 by tumor viruses ［J］. Naunyn-schmiedebergs Archives of Pharmacology, 2015, 388(2): 207-224.

[8] [8] MCCORKLE J R, LEONARD M K, KRANER S D, et al. The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma ［J］. Cancer Genomics & Proteomics, 2014, 11(4): 175-194.

[9] [9] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses ［J］. Nucleic Acids Research, 2017, 45(W1): W98-W102.

[10] [10] LI T, FU J, ZENG Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells ［J］. Nucleic Acids Research, 2020, 48(W1): W509-W514.

[11] [11] CERAMI E, GAO J, DOGRUSOZ U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data ［J］. Cancer Discovery, 2012, 2(5): 401-404.

[12] [12] SZKLARCZYK D, GABLE A L, LYON D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets ［J］. Nucleic Acids Research, 2019, 47(D1): D607-D613.

[13] [13] ZHOU Y, ZHOU B, PACHE L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets ［J］. Nature Communications, 2019, 10(1): 1523.

[14] [14] ZHANG Q, MCCORKLE J R, NOVAK M, et al. Metastasis suppressor function of NM23-H1 requires its 3'-5' exonuclease activity ［J］. International Journal of Cancer, 2011, 128(1): 40-50.

[15] [15] KIM A W, BATUS M, MYINT R, et al. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer ［J］. Lung Cancer, 2011, 71(2): 186-190.

[16] [16] LINDER N, BUTZOW R, LASSUS H, et al. Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma ［J］. Gynecologic Oncology, 2012, 124(2): 311-318.

[17] [17] LI R, PENG C, ZHANG X, et al. Roles of Arf6 in cancer cell invasion, metastasis and proliferation ［J］. Life Sciences, 2017, 182: 80-84.

[18] [18] WANG X, XIONG H, LIANG D, et al. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients ［J］. BMC Cancer, 2020, 20(1): 378.

[19] [19] WANG Y, WANG Y, XU L, et al. CD4 + T cells promote renal cell carcinoma proliferation via modulating YBX1 ［J］. Experimental Cell Research, 2018, 363(1): 95-101.

[20] [20] DUNN G P, BRUCE A T, IKEDA H, et al. Cancer immunoediting: from immunosurveillance to tumor escape ［J］. Nature Communications, 2002, 3(11): 991-998.

[21] [21] GARRIDO F, CABRERA T, APTSIAURI N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy ［J］. International Journal of Cancer, 2010, 127(2): 249-256.

[22] [22] FRUCI D, BENEVOLO M, CIFALDI L, et al. Major histocompatibility complex class I and tumour immuno-evasion: how to fool T cells and natural killer cells at one time ［J］. Current Oncology, 2012, 19(1): 39-41.

[23] [23] BENOIT M, DESNUES B, MEGE J L. Macrophage polarization in bacterial infections ［J］. Journal of Immunology, 2008, 181(6): 3733-3739.

[24] [24] SCHMIEDER A, MICHEL J, SCHONHAAR K, et al. Differentiation and gene expression profile of tumor-associated macrophages ［J］. Seminars in Cancer Biology, 2012, 22(4): 289-297.

[25] [25] WATKINS S K, EGILMEZ N K, SUTTLES J, et al. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo ［J］. Journal of Immunology, 2007, 178(3): 1357-1362.

[26] [26] FRIDLENDER Z G, SUN J, KIM S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN ［J］. Cancer Cell, 2009, 16(3): 183-194.

[27] [27] GUILLEREY C, HUNTINGTON N D, SMYTH M J. Targeting natural killer cells in cancer immunotherapy ［J］. Nature Communications, 2016, 17(9): 1025-1036.